Sugi Predict

Sugi Predict / Compounds / SCHEMBL829702

SCHEMBL829702

SCHEMBL829702

CCCCCNC(=N)NC(=O)c1nc(Cl)c(N)nc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCNN1A P37088 18/20 0.59
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ HPGD P15428 3/20 0.43
▸ HSD17B10 Q99714 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ NFKB1 P19838 2/20 0.43
▸ THPO P40225 2/20 0.43
▸ HIF1A Q16665 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ GMNN O75496 2/20 0.43
▸ PMP22 Q01453 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ STAT6 P42226 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ GLA P06280 2/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12433373 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL13090579 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14190122 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14190128 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14088251 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14190133 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL14190132 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL13090581 0.99 SCNN1A (0.61) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3799015 0.96 SCNN1A (0.57) SCNN1AALDH1A1KDM4EHPGDHSD17B10
SCHEMBL13165922 0.92 SCNN1A (0.51) SCNN1AALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023146896-A1 BICYCLIC-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146892-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
US-20180111907-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES PARION SCIENCES, INC. 2018-04-26 — — US disclosed
US-9878988-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2018-01-30 — — US disclosed
US-9593084-B2 Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity PARION SCIENCES, INC. (US) 2017-03-14 — — US disclosed
US-9593084-B2 Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity PARION SCIENCES, INC. (US) 2017-03-14 — — US disclosed
US-9586910-B2 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide PARION SCIENCES, INC. (US) 2017-03-07 — — US disclosed
US-9586910-B2 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide PARION SCIENCES, INC. (US) 2017-03-07 — — US disclosed
US-20160122306-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES PARION SCIENCES, INC. (US) 2016-05-05 — — US disclosed
US-9260398-B2 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. (US) 2016-02-16 — — US disclosed
US-20140031371-A1 POLY AROMATIC SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2014-01-30 — — US disclosed
US-8575176-B2 Heteroaromatic pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. (US) 2013-11-05 — — US disclosed
US-8288391-B2 Epithelial Sodium Channel and Acid Sensitive Ion Channel modulators; blocking or enhancing salt and sour tastes; additives in chocolate, ice cream, beverages, candies, or pet foods; side effect reduction PARION SCIENCES, INC. (US) 2012-10-16 — — US disclosed
US-20120116083-A1 HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2012-05-10 — — US disclosed
US-8143256-B2 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics PARION SCIENCES, INC. (US) 2012-03-27 — — US disclosed
US-8143256-B2 5-(4-{4-[A7-(3,5-diamino-6-chloropyrazine-2 carbonyl)guanadio]butyl}-piperazin-1-yl)pentanoic acid (3-dimethylaminopropyl) amide; hydration of mucosal surfaces; Chronic bronchitis; cystic fibrosis; more potent; absorbed slower; target kidney in treating cardiovascular disease; diuretics PARION SCIENCES, INC. (US) 2012-03-27 — — US disclosed
US-8124607-B2 Poly aromatic pyrazinoylguanidine sodium channel blockers PARION SCIENCES, INC. (US) 2012-02-28 — — US disclosed
US-20090214444-A1 POLY AROMATIC SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. (US) 2009-08-27 — — US disclosed
US-20080293740-A1 METHOD OF TREATING ACID-SENSING ION CHANNEL MEDIATED PAIN, COUGH SUPPRESSION, AND CENTRAL NERVOUS SYSTEM DISORDERS PARION SCIENCES, INC. (US) 2008-11-27 — — US disclosed
US-20080249109-A1 PYRAZINOYLGUANIDINE COMPOUNDS FOR USE AS TASTE MODULATORS PARION SCIENCES, INC. (US) 2008-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249109-A1 PYRAZINOYLGUANIDINE COMPOUNDS FOR USE AS TASTE MODULATORS TAS2R5, TAS2R9, TAS2R19 SCNN1A 65/4885ALDH1A1 1849/4885KDM4E 2672/4885
US-20080293740-A1 METHOD OF TREATING ACID-SENSING ION CHANNEL MEDIATED PAIN, COUGH SUPPRESSION, AND CENTRAL NERVOUS SYSTEM DISORDERS ASIC1, ASIC3, TRPV1 SCNN1A 75/4885ALDH1A1 1073/4885KDM4E 4543/4885
US-20120116083-A1 HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS HCN4, SCN2B, KCNH1 SCNN1A 16/4885ALDH1A1 994/4885KDM4E 3151/4885
US-20090214444-A1 POLY AROMATIC SODIUM CHANNEL BLOCKERS HCN4, SCN2B, SCNN1B SCNN1A 11/4885ALDH1A1 1287/4885KDM4E 2068/4885
US-20140031371-A1 POLY AROMATIC SODIUM CHANNEL BLOCKERS HCN4, SCN2B, SCNN1B SCNN1A 11/4885ALDH1A1 1287/4885KDM4E 2068/4885
US-20160122306-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES SCNN1B, SCNN1A, SCNN1G SCNN1A 2/4885ALDH1A1 2317/4885KDM4E 3036/4885
US-20180111907-A1 DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES SCNN1B, SCNN1A, SCNN1G SCNN1A 2/4885ALDH1A1 2317/4885KDM4E 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.